欧美国产日韩在线免费观看-欧美日韩成人激情一区二区-欧美久久综合一区二区-亚洲av寂寞少妇久久

您好, 歡迎來到化工儀器網(wǎng)

| 注冊| 產(chǎn)品展廳| 收藏該商鋪

13774214275

products

目錄:杭州斯達(dá)特生物科技有限公司>>蛋白>>藥物靶點和Fc受體>> UA011105BDCA-2/DLEC Fc Chimera Protein, Cynomolgus

BDCA-2/DLEC Fc Chimera Protein, Cynomolgus
  • BDCA-2/DLEC Fc Chimera Protein, Cynomolgus
參考價 1280
具體成交價以合同協(xié)議為準(zhǔn)
參考價 1280
具體成交價以合同協(xié)議為準(zhǔn)
  • 品牌 Starter/斯達(dá)特
  • 型號 UA011105
  • 廠商性質(zhì) 生產(chǎn)商
  • 所在地 南京市
屬性

>

更新時間:2025-06-17 10:08:44瀏覽次數(shù):11評價

聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息,謝謝!

同類優(yōu)質(zhì)產(chǎn)品

更多產(chǎn)品
BDCA-2/DLEC Fc Chimera Protein, Cynomolgus

Dendritic Cell Lectin (DLEC), also known as BDCA-2, CD303, HECL, and alternatively designated as CLEC4C/CLECSF11/CLECSF7, is a 38 kDa type II transmembrane protein belonging to the C-type lectin family. DLEC is selectively expressed in plasmacytoid dendritic cells (pDCs) and its expression is downregulated as these cells mature.
pDCs are integral to the innate immune response, particularly in the production of IFN-alpha/beta upon exposure to Toll-like receptor (TLR) 7 and TLR9 agonists, such as microbial CpG DNA. The ligation of DLEC on pDCs with specific antibodies has been shown to attenuate the CpG-stimulated production of interferons and to modulate the Th1 response. Monoclonal antibodies targeting CLEC4C have demonstrated efficacy in achieving disease control in patients with cutaneous lupus erythematosus.
The suppression of IFN-alpha production mediated by CLEC4C is regulated through the masking and unmasking of galactose moieties on the protein. This mechanism represents a novel potential strategy for modulating immune responses in various pathological conditions.

會員登錄

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

標(biāo)簽:
保存成功

(空格分隔,最多3個,單個標(biāo)簽最多10個字符)

常用:

提示

您的留言已提交成功!我們將在第一時間回復(fù)您~
在線留言

會員登錄

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

該信息已收藏!
標(biāo)簽:
保存成功

(空格分隔,最多3個,單個標(biāo)簽最多10個字符)

常用:
熱線電話 在線詢價